Teva Q3 2025: revenue $4.48B (+3%), non-GAAP EPS $0.78; Austedo outlook raised; TAPI sale restart

TEVA PHARMACEUTICAL INDUSTRIES LTD

2025-Q3 EPS reported $0.80 revenue$12,547,000,000

Revenue $4.48B (+3% YoY); GAAP EPS $0.37, non-GAAP EPS $0.78 (vs $0.69 YoY).
Austedo revenue $618M (+38% YoY); 2025 outlook raised to $2.05B-$2.15B (from $1.95B-$2.05B).
Non-GAAP operating margin 28.9% (+86 bps YoY); on track for 30% target by 2027.
Exclusive TAPI sale discussions terminated; renewed sales process initiated; divestiture intent maintained.
Full-year 2025 non-GAAP EPS guidance raised to $2.55-$2.65 (midpoint +$0.025); FCF unchanged $1.6B-$1.9B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.